Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase year-on-year [1] Financial Performance - The company achieved an operating income of 1.539 billion RMB, representing a 5.95% increase compared to the previous year [1] - The net profit attributable to the parent company's shareholders was 267 million RMB, showing a year-on-year growth of 19.17% [1] - Basic earnings per share were reported at 0.67 RMB [1] Market and Sales Strategy - The overall execution of orthopedic bulk procurement remained stable during the reporting period, with leading domestic brands increasing their market share [1] - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around professional departments to enhance marketing efficiency [1] - There is a further segmentation of product lines through detailed management by sales divisions, which aims to improve the professional capabilities and focus of the sales team for more precise clinical services and academic leadership [1] - The company is concentrating on key surgical procedures with multi-product line collaborative sales, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [1]